Regular ArticleP2Y12, a New Platelet ADP Receptor, Target of Clopidogrel
References (24)
- et al.
Clopidogrel, a novel antiplatelet and antithrombotic agent
Cardiovasc. Drug Rev.
(1993) - et al.
Pharmacology of ticlopidine and clopidogrel
Haematology
(2000) Lancet
(1996)- et al.
Binding of [3H]-2-methylthio ADP to rat platelets—Effect of clopidogrel and ticlopidine
J. Pharmacol. Exp. Ther.
(1994) - et al.
Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase
Arterioscler. Thromb.
(1992) - et al.
Identification and biological activity of the active metabolite of clopidogrel
Thromb. Haemost.
(2000) - et al.
Role of P2Y1 purinoceptor in ADP-induced platelet activation
FEBS Lett.
(1998) - et al.
Characterization of P2x1 purinoreceptors on rat platelets: Effect of clopidogrel
Br. J. Haematol.
(1997) - et al.
ADP is the cognate ligand for orphan G-protein coupled receptor SP1999
JBC
(2001) - et al.
Identification of the platelet ADP receptor targeted by antithrombotic drugs
Nature
(2001)
Rapid isolation of highly productive recombinant Chinese hamster ovary cell lines
Gene
Cited by (219)
P2Y12 inhibitor clopidogrel inhibits renal fibrosis by blocking macrophage-to-myofibroblast transition
2022, Molecular TherapyCitation Excerpt :Clopidogrel, an FDA-approved P2Y12 inhibitor, is one of the most prescribed medicines for the treatment of cardiovascular disease.31 After intestinal absorption and liver metabolism, clopidogrel can be converted into an active metabolite, which is essential for inhibition of P2Y12 receptor, by binding irreversibly to the cysteine residue of P2Y12 extracellular domain to block the binding of ADP to a purinergic receptor at the platelet surface, thereby inhibiting ADP-induced platelet aggregation to exert the antithrombotic effect.32–34 Thus, clopidogrel has been shown to have a beneficial effect on cardiovascular diseases, although it increases the risk of bleeding.35
Medical gas plasma promotes blood coagulation via platelet activation
2021, BiomaterialsG protein-coupled purinergic P2Y receptor oligomerization: Pharmacological changes and dynamic regulation
2021, Biochemical PharmacologyBiologically active metabolites in drug discovery
2021, Bioorganic and Medicinal Chemistry LettersAtherosclerosis: Conventional intake of cardiovascular drugs versus delivery using nanotechnology – A new chance for causative therapy?
2021, Journal of Controlled Release
- 1
To whom correspondence should be addressed. Fax: (33) 05 61 16 22 86. E-mail: [email protected].